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ver the next few years, we can 
expect to see the licensing 
of one or more prophylactic 
vaccines against human papillomavirus 
(HPV) infection, considered a 
necessary precursor to cervical cancer. 
Among over 40 known types of HPV, 
15 have been identiﬁ  ed as being “high 
risk” or oncogenic. The vaccines 
will likely target at least two of these 
oncogenic types, HPV types 16 and 18, 
which have been found to contribute 
to nearly 70% of cervical cancer cases 
worldwide—although there is large 
variation in contribution by geographic 
region [1,2]. Although cytology-based 
cervical cancer screening has been 
successful in decreasing the incidence 
of invasive cancer in many developed 
countries, vaccination may be the most 
promising intervention from a global 
perspective—reducing the burden 
of cervical cancer in resource-poor 
settings, where most cases occur.
    Why a Mathematical Model?
    Mathematical models can be useful 
tools in exploring disease trends and 
health consequences of interventions 
in a population over time. In the case 
of cervical cancer, in which the time 
from acquisition of HPV infection to 
development of invasive cancer can be 
two decades or more, models can be 
used to translate short-term ﬁ  ndings 
from vaccine trials into predictions of 
long-term health outcomes [3–9]. In a 
new study in   PLoS Medicine  , Barnabas 
and colleagues present a particular 
type of mathematical model known as 
a dynamic model to directly assess the 
effect of sexual transmission of HPV 
type 16 in a Finnish population [10]. 
This model is the ﬁ  rst to capitalize on 
empirical data on sexual history and 
HPV seroprevalence from a single 
population to estimate the transmission 
of HPV 16 between men and women, 
and to explore the impacts of risk 
factors on observed changes in cervical 
cancer incidence over time.
    What Did the Researchers Do?
    The model itself, although technically 
complicated, is conceptually 
straightforward when broken down into 
its vital parts. Adult men and women 
were modeled separately, and in the 
model they formed partnerships over 
time based on sexual history data from 
Finnish adults within the period of 
1971–1999. HPV type 16 is transmitted 
between men and women in sexual 
relationships at a rate that is dependent 
on the prevalence of HPV 16 in the 
population, as well as on age and sexual 
activity level; women infected with HPV 
16 can further develop precancerous 
lesions and invasive cervical cancer 
(ICC).
    As a general rule, not all parameters 
in a model are known, which requires 
adjustment (or “calibration”) of model 
inputs to observed outcomes. One of 
the biggest unknowns in Barnabas and 
colleagues’ model was the transmission 
rate of HPV 16 between partners. 
Since we cannot observe transmission 
per partnership directly, the authors 
calibrated this parameter using a 
maximum likelihood–based approach, 
which, in simple terms, derives an 
estimate of this parameter that achieves 
the best model ﬁ  t to the observed 
HPV seroprevalence data from Finnish 
women. Borrowing other model inputs 
from previously published models 
[11,12], the authors used their model 
to examine the contributions of risk 
factors (i.e., age at sexual debut, 
number of sexual partners, and 
smoking patterns) on the observed 
increase in ICC among 35- to 39-year-
old women over time. They also used 
the model to consider a series of “what 
if?” scenarios pertaining to vaccination 
against HPV 16 on incidence of HPV 
16–associated ICC. 
    The Study’s Key Findings
    In estimating the transmission rate 
of HPV 16 between men and women, 
the authors found that the model 
underestimated the empirically 
observed seroprevalence of HPV 16 
when they assumed the same rate of 
partner change as reported in the 
Finnish surveys. Consequently, they 
explored the effects on the model of 
increasing the number of new partners 
per year, and derived a transmission 
rate of 0.6 per partner after doubling 
the reported rate of sexual partner 
change, and 0.4 after assuming that the 
number of reported lifetime partners 
is actually the number of new partners 
per year.
    Neither changes in sexual behavior 
nor smoking patterns were found 
to contribute substantially to the 
rising trends in HPV 16–associated 
cervical cancer over time for 35- to 
39- year-old women. But the authors 
assumed only a one-time shift in age 
of sexual debut and in number of 
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partners in the model, and assumed 
that smoking patterns of women were 
relatively constant from the late 1970s 
through the mid-1990s, as suggested 
by the empirical data. The authors 
note that other risk factors such as 
oral contraceptive use and parity may 
contribute to the changing patterns of 
incidence over time, but these were not 
included in the model.
    For the most part, the analyses 
evaluating vaccination policies 
showed intuitive results: vaccination 
of both men and women has a small 
incremental beneﬁ  t compared 
with vaccination of women alone; 
vaccine beneﬁ  t decreases as age at 
vaccination—after sexual debut—
increases; and a shorter duration of 
vaccine-induced immunity is shown 
to be associated with higher cancer 
incidence, particularly if waning 
immunity coincides with higher rates 
of persistent infections among older 
women. When vaccine protection is 
assumed to be lifelong, cytology-based 
screening is predicted to add little 
beneﬁ  t to vaccination alone, but the 
outcome reported is for ICC associated 
with HPV 16 only. It is important to 
bear in mind that even under the 
most favorable conditions of vaccine 
coverage, efﬁ  cacy, and duration, 
some form of screening will likely be 
necessary to reduce ICC associated with 
the 13 or more other oncogenic HPV 
types not targeted by the vaccine.
    Study Limitations and Implications
    This model represents an impressive 
step forward in the simulation of HPV 
transmission and in the exploration 
of the effects of risk factors and 
vaccination over time. However, 
the conclusions drawn from this 
analysis should be interpreted with an 
appreciation of the model’s limitations. 
Most obviously, the model in its 
current form reﬂ  ects HPV infection 
and cervical cancer associated with 
only a single HPV type. Therefore, the 
model cannot provide a comprehensive 
picture of cervical cancer over time 
after the introduction of vaccination; 
indeed, another 30% of cervical cancer 
cases (and more in some regions of 
the world) are caused by oncogenic 
HPV types other than type 16. And 
while the potential for cross-protection 
or cross-reactivity among HPV types 
seems plausible, this potential cannot 
be explored using a single-type HPV 
model such as this one. 
    Furthermore, the authors conclude 
that the transmission probability per 
partnership lies above 0.4, which is 
based on the extreme assumption that 
the number of new annual partners is 
equivalent to the number of reported 
lifetime partners. While there are known 
biases in sexual behavior survey data, 
this value of per-partner transmission 
relies on many other uncertain 
parameters and assumptions in the 
model. Assumptions such as lifelong 
acquired immunity, where women 
are no longer susceptible to repeat 
infections after initial infection and 
clearance, are acknowledged by the 
authors to affect the estimated HPV 16 
transmission probability, but are not 
explored in the analysis. Holding all 
else constant, we would expect to see 
the transmission probability decrease 
below 0.4 if the assumption of lifelong 
acquired immunity is relaxed. Lastly, 
trends in sexual behavior as well as other 
risk factors will differ in other settings, 
meaning that Barnabas and colleagues’ 
ﬁ  ndings are not generalizable to other 
settings. The model itself, however, may 
be used for analyses in other countries, 
but preferably after a recalibration of 
the model using available country- or 
region-speciﬁ  c data.
    We can anticipate better data 
on the longitudinal nature of HPV 
infections, including immunity and 
interactions among multiple types and 
even the transmission rate of HPV 
among partners. In the meantime, 
models such as the current one can be 
valuable tools for exploring the impacts 
of known risk factors in the cervical 
carcinogenesis pathway for a single 
HPV type and for gaining insights 
into hypothetical scenarios of efﬁ  cacy, 
duration, and long-term impact of type-
speciﬁ  c vaccination.   
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